

Biotinylated Ubiquitin

Modifier

Alternate Names: Ribosomal Protein S27a, CEP80, UBA80, UBCEP1, UBCEP80, HUBCEP80, RPS27A

Cat. No. 60-0121-100
Lot. No. 30219

Quantity: 100 µg
Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

Background

Biotinylated ubiquitin is a powerful research tool for detecting ubiquitylation *in vitro*. The biotinyl moiety allows for the use of high affinity streptavidin detection reagents and allows for the isolation of ubiquitin conjugated substrates by avidin/streptavidin purification methods.

Ubiquitin is a highly conserved protein that plays a key role in the ubiquitylation pathway. Ubiquitin is found only in eukaryotic organisms throughout which it shows strong sequence conservation (Wilkinson, 1995). The ubiquitin protein is present in all cell types and found either in free form or conjugated to proteins through a covalent bond between its C-terminal glycine and the ε-amino group of lysine residues or the α-amino group of an N-terminal methionine; a process known as ubiquitination or ubiquitylation. Ubiquitylation is an essential cellular process affected by a multi-enzyme cascade involving three classes of enzyme known as activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). E1 activates ubiquitin in an ATP-dependent manner resulting in the formation of a thioester linkage between the carboxy terminus of ubiquitin and the E1 enzyme. Sequential, transient thioester bonds are then generated between the carboxy terminus of ubiquitin and specific cysteines of the E2 and – in some instances – of the E3 enzymes (Bonifacino and Weissman, 1998). Ultimately, an isopeptide bond is formed between the glycine carboxy terminus of ubiquitin and an ε-amino group of a lysine

Continued on page 2

Physical Characteristics

Species: bovine

Source: erythrocytes

Quantity: 100 µg

Concentration: 1.0 mg/ml

Formulation: 50 mM HEPES pH 7.5,
150 mM sodium chloride,
2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~9.8 kDa

Purity: >95% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C;
aliquot as required

Protein Sequence:


**MQIFVK(biotinyl)TLTGKTITLEVEPSDTIE
NVKAKIQDKEGIPPDQQLIFAGK(biotinyl)
QLEDGRTLSDYNIQKESTLHLVLRLLGG**

Ubiquitin (regular text): Start **bold italics** (amino acid residues 1-76)
Accession number: P62990.1

Mass spectrometry confirmed that the predominant sites of biotinylation are on Lys6 and Lys48 although other Lys residues may be biotinylated to a lesser degree.


Quality Assurance

Purity:
4-12% gradient SDS-PAGE
InstantBlue™ staining
Lane 1: MW markers
Lane 2: 1 µg Biotinylated
Ubiquitin



Protein Identification:

Confirmed by mass spectrometry.



E3 ligase assay: Activity of the biotinylated ubiquitin was validated through its ability to be incorporated into polyubiquitin chains in the presence of the E1 activating enzyme His-UBE1, the E2 conjugating enzyme His-UBE2D3 (UbcH5c) and the E3 ligase His-IDOL. Incubation of biotinylated ubiquitin for 60 minutes at 30°C in the presence of His-IDOL, His-UBE1, His-UBE2D3 and ATP (Lane 1) was compared alongside two control reactions with either ATP (Lane 2) or His-IDOL Lane 3) excluded from the reaction. Ubiquitin conjugates were identified by Western blotting using an HRP-linked streptavidin conjugate and these were observed only in the presence of both ATP and His-IDOL. The reaction (Lane 1) contains a number of ubiquitylated and biotinylated species.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

Biotinylated Ubiquitin

Modifier

Alternate Names: Ribosomal Protein S27a, CEP80, UBA80, UBCEP1, UBCEP80, HUBCEP80, RPS27A

Cat. No. 60-0121-100
Lot. No. 30219

Quantity: 100 µg
Storage: -70°C



FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Continued from page 1

residue on a target protein (mono-ubiquitylation) or on another ubiquitin resulting in the generation of chains of ubiquitin (poly-ubiquitylation) which may be Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48 or Lys-63 linked (Komander, 2009). Ubiquitin chains may also be linear in nature, formed via the conjugation of the activated glycine residue of one ubiquitin moiety to the α -amino group at the N-terminus of another ubiquitin. Specific ubiquitin chain types adopt distinct conformations which are likely to be important in respect of their functions. Although some functionalities have been determined for certain chain types, the roles of many of these structures remain to be fully elucidated (Komander, 2009). In respect of Lys-48 and Lys-63 chain types, some key roles have been determined: Lys-48 linked chains direct substrates towards 26S proteasome mediated degradation (Verma *et al.*, 2004), whereas roles for Lys-63 linked chains include activation of the NF- κ B pathway and mediation of steps of the DNA repair pathway (DiFiglia *et al.*, 1997; Rahighi *et al.*, 2009; Tokunaga *et al.*, 2009). Interestingly, proteins constituting many types of pathological inclusion bodies may be poly-ubiquitylated, however these may be resistant to degradation. For example poly-ubiquitylated huntingtin accumulates at neuronal intranuclear inclusions (NIIs) and dystrophic neuritis in the striatum and cortex of patients affected by Huntington's disease (DiFiglia *et al.*, 1997).

References:

- Bonifacino JS, Weissman AM (1998) Ubiquitin and the control of protein fate in the secretory and endocytic pathways. *Annu Rev Cell Dev Biol* **14**, 19-57.
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* **277**, 1990-3.
- Komander D (2009) The emerging complexity of protein ubiquitination. *Biochem Soc Trans* **37**, 937-53.
- Rahighi S, Ikeda F *et al.* (2009) Specific recognition of linear ubiquitin chains by NEMO is important for NF- κ B activation. *Cell* **136**, 1098-109.
- Tokunaga F, Sakata S *et al.* (2009) Involvement of linear polyubiquitylation of NEMO in NF- κ B activation. *Nat Cell Biol* **11**, 123-32.
- Verma R, Oania R, Graumann J, Deshaies RJ (2004) Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. *Cell* **118**, 99-110.
- Wilkinson KD (1995) Roles of ubiquitylation in proteolysis and cellular regulation. *Annu Rev Nutr* **15**, 161-89.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0